Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals (VRPX) is advancing non-opioid pain management through innovative drug delivery systems, including metered-dose sprays and liposomal formulations. This news hub provides investors and industry observers with timely updates on preclinical developments, regulatory milestones, and strategic partnerships.
Our curated collection of VRPX news offers essential insights into the company's progress in developing alternatives to traditional pain therapies. Track updates across key areas including product pipeline advancements, intellectual property developments, and global research collaborations that shape the future of pain treatment.
Discover official press releases detailing Virpax's work on enkephalin-based therapies and hydrogel encapsulation technologies. Stay informed about critical updates through verified financial disclosures and scientific progress reports, all maintained in one centralized location for efficient research.
Bookmark this page for ongoing access to VRPX's latest achievements in pharmaceutical innovation. Check regularly for new developments in their mission to enhance therapeutic outcomes while reducing opioid dependency risks.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced its Q1 2024 results and recent developments. The company reported an increase in general and administrative expenses to $1.7M and R&D expenses to $1.6M, leading to an operating loss of $3.2M. Cash reserves stood at $1.9M as of March 31, 2024. Key highlights include the positive results of the Probudur™ Maximum Tolerated Dose Study, ongoing development of Envelta™ and NobrXiol™, and a settlement agreement with Sorrento Therapeutics and Scilex Pharmaceuticals. The company is also seeking additional grants and licensing opportunities. CEO Gerald W. Bruce expressed optimism about the future despite the financial challenges.
Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine. The formulation demonstrated the potential to offer rapid onset and prolonged action, marking significant progress towards completing preclinical studies and filing for an Investigational New Drug Application (IND) by the end of the year.
